Can Global Healthcare Systems Stay Resilient Without Reinventing Pharmaceutical Manufacturing?

As global healthcare systems confront increasingly fragile supply chains, rising biologics complexity, geopolitical fragmentation, and mounting pressure on drug accessibility, pharmaceutical resilience is rapidly evolving from a procurement concern into a broader systems-level challenge.

That shift formed the central focus of the “Global Pharmaceutical Resilience Summit,” hosted by the Industrial Technology Research Institute (ITRI), with support from Taiwan’s Department of Industrial Technology (DoIT) under the Ministry of Economic Affairs (MOEA). Rather than framing resilience solely around emergency preparedness or domestic production, the summit positioned pharmaceutical resilience as an integrated challenge spanning regulation, manufacturing, clinical systems, quality oversight, and international collaboration. Built around three core pillars — regulatory foundations, advanced manufacturing, and drug accessibility — the discussions explored how digitalized Clinical and Manufacturing Control (CMC), Quality by Design and Decision Making (QbDD), AI-supported systems, and cross-domain integration may reshape the future of pharmaceutical manufacturing and supply stability globally.

While Taiwan served as the operational backdrop, the discussions themselves reflected broader international pressures now affecting pharmaceutical systems across the U.S., Europe, Japan, and other major healthcare markets: concentrated API manufacturing, aging populations, antimicrobial resistance (AMR), manufacturing-quality failures, increasingly complex therapies, and growing demands for supply predictability. The summit brought together stakeholders across industry, regulation, healthcare, and manufacturing, including former U.S. FDA Commissioner Stephen M. Hahn, Taiwan National Health Insurance Administration Deputy Director-General Chia-Jui Yen, Taiwan Generic Pharmaceutical Association President Tiffany Chen, and representatives from organizations including the UK’s CPI and Bora Pharmaceuticals.

From Supply Security to System-Level Resilience

One of the clearest themes across the summit was that pharmaceutical resilience can no longer be addressed through stockpiling or emergency sourcing strategies alone. Speakers repeatedly argued that resilience now depends on whether healthcare systems can maintain manufacturing quality, regulatory continuity, patient access, and operational flexibility simultaneously during prolonged disruption.

Chien-Cheng Tai, Senior Specialist at Taiwan’s Ministry of Economic Affairs (MOEA), outlined how decades of globalization and cost optimization created heavily concentrated pharmaceutical manufacturing ecosystems, particularly in active pharmaceutical ingredients (APIs). According to Tai, roughly 64% of global API production remains concentrated in China and India — approximately 44% and 20% respectively — creating structural vulnerabilities that extend far beyond simple logistics risk.

Rather than advocating deglobalization, Tai framed the issue around diversification and trusted international partnerships. He identified four major risks associated with concentrated pharmaceutical supply chains: geopolitical instability, unexpected disruptions, market concentration and price volatility, and limitations in overseas manufacturing quality oversight. “Diversification is not about replacing one country with another,” he explained during the summit. “It’s about creating a more resilient and diverse supply chain.”

That broader philosophy surfaced repeatedly throughout the discussions. Tai emphasized that pharmaceutical resilience is not built through isolation, but through trust-based international networks capable of maintaining continuity during crisis conditions. “A resilient pharmaceutical system is not built on one country, one supply chain — it’s built on trust,” he noted.

The concept of “trusted partnerships” later resurfaced in discussions surrounding regulatory interoperability, distributed manufacturing, and global supply diversification. Multiple speakers suggested that future pharmaceutical resilience may depend less on complete domestic self-sufficiency and more on diversified international manufacturing ecosystems supported by transparent regulatory standards and aligned quality systems.

Panelists discussed how pharmaceutical systems can balance long-term resilience with global competitiveness, with several speakers emphasizing that resilience should not be viewed as the opposite of globalization. Instead, it was repeatedly stated that diversified manufacturing, trusted international partnerships, and regulatory interoperability may become increasingly important as countries attempt to reduce overdependence on concentrated pharmaceutical supply chains while maintaining innovation and scalability. Image: GeneOnline

Drug Shortages Are Increasingly Being Viewed as Manufacturing and Quality Failures

Another major narrative shift throughout the summit involved how pharmaceutical shortages themselves are being interpreted. Several speakers argued that shortages are no longer simply procurement or raw material problems, but increasingly reflect weaknesses in manufacturing systems, operational visibility, and quality oversight.

Stephen Hahn repeatedly pointed toward manufacturing quality as a central issue, citing FDA findings suggesting that roughly 70% of U.S. drug shortages originate from manufacturing-quality failures rather than API scarcity alone.

That framing substantially changes the resilience conversation. Instead of focusing purely on inventory accumulation, discussions increasingly centered on predictive manufacturing systems, continuous production models, AI-assisted monitoring, and integrated digital quality infrastructure capable of identifying risk before disruption occurs.

Hahn described the pandemic as a “stress test” that exposed structural weaknesses already embedded within global pharmaceutical systems, including fill-finish bottlenecks, concentrated manufacturing dependence, demand forecasting limitations, and insufficient predictive shortage monitoring systems. At the same time, he cautioned against oversimplified anti-globalization narratives, stressing instead the need for balanced international cooperation combined with stronger supply resilience frameworks. “Globalization is here,” Hahn remarked during the discussions, arguing that future healthcare security will depend on balancing global collaboration with strategic resilience planning.

His presentation also expanded the resilience discussion beyond pandemics alone. Hahn repeatedly referenced antimicrobial resistance (AMR), cyber vulnerabilities, geopolitical disruption, and climate-related instability as emerging risks capable of placing sustained pressure on global pharmaceutical systems in the coming decade.

Regulatory Systems Are Being Forced to Modernize Alongside Advanced Therapies

As pharmaceutical products become increasingly complex — particularly across biologics, cell therapies, mRNA platforms, and radiopharmaceuticals — speakers repeatedly emphasized that regulatory systems themselves are undergoing structural transformation.

Lan-Hui Chih, Division Director at Taiwan FDA, described the industry as moving away from traditional “quality by testing” approaches toward predictive “quality by design” and “quality by decision making” frameworks.

Her presentation focused heavily on integrating AI-supported analytics, FAIR data ecosystems, continuous manufacturing, process analytical technologies (PAT), and predictive quality systems directly into pharmaceutical oversight models. Rather than relying primarily on retrospective review or isolated inspections, regulators are increasingly exploring real-time monitoring systems capable of continuously evaluating manufacturing performance and process stability.

“We are moving away from being document-centered toward entirely data-driven environments,” Chih explained, outlining how regulators are beginning to explore AI-enhanced predictive release systems, lifecycle monitoring, and digitally integrated quality oversight frameworks.

The broader implication throughout the summit was that pharmaceutical manufacturing, regulatory science, and digital infrastructure are becoming increasingly interconnected. Across the U.S., Europe, and Asia, regulators are simultaneously exploring rolling reviews, reliance frameworks, real-world evidence integration, and advanced manufacturing oversight models designed to accelerate responsiveness without compromising safety or quality standards.

Resilience Is Also Becoming an Economic Challenge

Despite widespread agreement on the need for modernization, the summit repeatedly returned to a more difficult reality: resilience is expensive.

Tiffany Chen, President of the Taiwan Generic Pharmaceutical Association, argued that pharmaceutical manufacturers — particularly generic drug companies — remain caught between rising resilience expectations and increasingly difficult economic conditions.

The industry, she noted, continues facing intense pricing pressure, low operating margins, fragmented manufacturing systems, and growing regulatory complexity while simultaneously being asked to invest in automation, digitalization, redundancy, and predictive manufacturing capabilities. “Policy alone is not enough,” Chen stressed during her presentation, warning of a widening gap between resilience ambitions and practical industrial execution.

Her discussion focused less on abstract transformation rhetoric and more on operational realities. Many pharmaceutical systems, she argued, still rely heavily on siloed operational environments, experience-driven decision-making, disconnected quality systems, and reactive investigation processes that struggle to respond quickly during disruption events.

Digital transformation, in this context, was presented not simply as an efficiency initiative, but as an operational resilience strategy. Connected manufacturing systems, integrated process visibility, predictive analytics, and AI-supported monitoring could potentially improve inventory stability, reduce downtime, accelerate deviation detection, and strengthen responsiveness across increasingly volatile global markets.

Drug Accessibility and Patient Safety Remain Central to the Resilience Debate

Beyond manufacturing and regulation, several sessions shifted the conversation toward healthcare delivery and patient safety itself.

Li-Jiuan Shen of National Taiwan University presented a structured “Escalation Ladder” framework illustrating how drug shortages progressively evolve from manageable substitution issues into broader clinical governance and patient safety challenges.

At lower levels, hospitals may respond through generic substitution or therapeutic alternatives. However, more severe shortages may eventually require emergency imports, specialized manufacturing, modified treatment prioritization, or leadership-level ethical intervention when no viable alternatives remain available.

Her presentation repeatedly emphasized that pharmaceutical fragility eventually extends far beyond supply logistics into frontline healthcare operations themselves — affecting treatment continuity, provider burden, patient anxiety, and broader healthcare system stability.

One line from the presentation summarized the broader concern succinctly: “Resilience is costly, but fragility is costlier.”

Meanwhile, Taiwan National Health Insurance Administration Deputy Director-General Chia-Jui Yen outlined how super-aged societies are simultaneously confronting rising chronic disease burdens, increasing cancer prevalence, workforce shortages, growing home healthcare demand, and escalating healthcare expenditures.

While discussed through Taiwan’s healthcare context, the pressures described closely mirror demographic and financing challenges now emerging across multiple advanced healthcare economies globally.

The second panel discussion focused on how pharmaceutical resilience increasingly extends beyond manufacturing into healthcare delivery, financing, and patient access. Speakers highlighted that drug shortages can rapidly escalate into broader clinical and operational challenges, with discussions emphasizing that sustainable pharmaceutical resilience will require closer integration between regulators, manufacturers, hospitals, and healthcare reimbursement systems to maintain long-term accessibility and system stability. Image: GeneOnline

Pharmaceutical Resilience Is Increasingly Being Treated as Critical Infrastructure

By the conclusion of the summit, the broader message had become increasingly clear: pharmaceutical resilience is no longer being treated solely as a supply chain concern or a temporary post-pandemic lesson.

Instead, speakers repeatedly framed resilience as foundational healthcare infrastructure — closely tied to manufacturing systems, digital infrastructure, regulatory agility, financing sustainability, and international coordination simultaneously.

The discussions suggested that future pharmaceutical competitiveness may depend less on maximizing manufacturing efficiency alone and more on whether healthcare systems can maintain continuity, quality, accessibility, and trust during prolonged disruption.

In that sense, the summit reflected a broader global transition already underway across healthcare systems worldwide: from reactive shortage management toward structural resilience design.

Author

Bernice Lottering